Moderna (Nasdaq: $MRNA): From FDA Refusal to AdCom Reversal — Why MFLUSIVA Is Now the New mRNA Sentiment Test

Moderna

Moderna’s seasonal flu vaccine story has changed sharply. The previous setup was built around a refusal-to-file shock and a PDUFA clock that never started. Now the same asset is heading into a public FDA advisory committee, with a formal August decision date, a reorganized commercial leadership structure, and a stock narrative that has moved from “regulatory roadblock” to “high-stakes execution window.”

Airlines and Travel Stocks Rebound as Peace Deal Hopes Drag Oil Lower: Why $AAL, $UAL, $DAL and $CCL Are Back on the Radar

Airlines june 2026

The travel trade is suddenly alive again. A preliminary U.S.-Iran agreement has pushed crude prices sharply lower, lifted risk appetite and brought airlines, cruise lines and tourism-linked stocks back into focus. The setup is not risk-free: the deal still has political loose ends, jet fuel remains volatile, and the airline industry is still working through one of the harshest cost shocks since the pandemic era. But the market has a simple reason to pay attention: lower oil can quickly change the narrative for every company that moves people.

The Truce That Changes the Tape: the U.S.-Iran Deal Reopens the Hormuz Question

truce Usa Iran

To understand the weight of the diplomatic turn announced between June 14 and June 15, it is necessary to go back to late February 2026, when the United States and Israel launched a military campaign against Iran. From that point, the conflict turned the Strait of Hormuz from a latent geopolitical risk into a central variable for oil, gas, inflation, interest rates and global equity markets.

Neumora Therapeutics (Nasdaq: $NMRA): Navacaprant Is Over, the Platform Story Moves to NMRA-511, NMRA-898 and NMRA-215

nmra

Neumora’s June 15, 2026 update turns the $NMRA story into a cleaner but more unforgiving special situation: the former lead depression asset has now failed across the Phase 3 KOASTAL program, the company is discontinuing navacaprant, cutting approximately 35% of its workforce and trying to preserve enough runway to prove whether the remaining neuroscience pipeline can still justify investor attention.

The Week Ahead: Fed Pressure, Trump Risk, SpaceX Aftershock and Small-Cap Catalysts to Watch — $SPRO $RKLB $PL

The week ahead jun 15

The week of June 15–19, 2026 arrives with an unusually dense mix of market-moving forces. It is not only a Federal Reserve week. It is not only a SpaceX aftershock week. It is not only a geopolitical oil-risk week. It is all of those things at once, compressed into four U.S. trading sessions because U.S. stock and bond markets are scheduled to close on Friday, June 19, for Juneteenth

FDA Pressure Builds Into Summer: Unicycive, Spero and Capricor Move Toward High-Stakes Decisions

UNCY SPRO CAPR

Unicycive, Spero and Capricor are approaching three very different regulatory moments: a phosphate-binder resubmission for dialysis patients, a partnered oral carbapenem opportunity in complicated urinary tract infection, and a rare-disease cell therapy review in Duchenne muscular dystrophy. The common thread is simple: each story now has a dated FDA catalyst, a defined risk window and a market setup that demands precision rather than hype.

RedHill Biopharma (Nasdaq: $RDHL): Opaganib Gets a Rare Pediatric Disease Designation, but the Bigger Story Is a High-Risk Pipeline Rebuild

RDHL

RedHill Biopharma gained renewed attention after the FDA granted Rare Pediatric Disease designation to opaganib for neuroblastoma, adding a potential Priority Review Voucher angle. But the full RDHL story involves far more than a single designation. With limited cash, going-concern risk, Nasdaq compliance pressure, and a pipeline requiring external funding, this remains a high-risk, high-volatility catalyst watch demanding strict risk discipline.